Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia

Experimental Hematology

Volumn 40, Issue 3, 2012, Pages 216-227

  Linden, Michael A ^a   Kirchhof, Nicole ^b   Carlson, Cathy S ^b   van Ness, Brian G ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; MYC PROTEIN; PROTEIN N RAS; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE NEOPLASM; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOGLOBULIN DEFICIENCY; LYMPHOCYTE PROLIFERATION; MICROSCOPY; MOUSE; MULTIPLE MYELOMA; N RAS GENE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; TRANSGENE;

3' UNTRANSLATED REGIONS; ANIMALS; B-LYMPHOCYTES; BCL-X PROTEIN; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; ENHANCER ELEMENTS, GENETIC; GENES, MYC; GENES, RAS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; LIVER; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); RECOMBINANT FUSION PROTEINS;

ANIMALIA; MURINAE; MUS; MUS MUSCULUS;

EID: 84856956542     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.11.006     Document Type: Article

References (36)

1. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374:324-339.
2. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 1997, 8:241-252.
3. Liu P., Leong T., Quam L., Billadeau D., Kay N.E., Greipp P., et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996, 88:2699-2706.
4. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001, 18:212-224.
5. Chng W.J., Gonzalez-Paz N., Price-Troska T., et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008, 22:2280-2284.
6. Chesi M., Brents L.A., Ely S.A., et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001, 97:729-736.
7. Crowder C., Kopantzev E., Williams K., Lengel C., Miki T., Rudikoff S. An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth. Oncogene 2003, 22:649-659.
8. Corradini P., Ladetto M., Voena C., et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 1993, 81:2708-2713.
9. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
10. Chaffin K.E., Beals C.R., Wilkie T.M., Forbush K.A., Simon M.I., Perlmutter R.M. Dissection of thymocyte signaling pathways by invivo expression of pertussis toxin ADP-ribosyltransferase. Embo J 1990, 9:3821-3829.
11. Linden M., Kirchhof N., Carlson C., Van Ness B. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood 2004, 103:2779-2786.
12. Billadeau D., Liu P., Jelinek D., Shah N., LeBien T.W., Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res 1997, 57:2268-2275.
13. Fulton R., Van Ness B. Kappa immunoglobulin promoters and enhancers display developmentally controlled interactions. Nucleic Acids Res 1993, 21:4941-4947.
14. Fulton R., van Ness B. Selective synergy of immunoglobulin enhancer elements in B-cell development: a characteristic of kappa light chain enhancers, but not heavy chain enhancers. Nucleic Acids Res 1994, 22:4216-4223.
15. Adams J.M., Harris A.W., Pinkert C.A., et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
16. Cheung W.C., Kim J.S., Linden M., et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004, 113:1763-1773.
17. O'Brien D.P., Oltz E.M., Van Ness B.G. Coordinate transcription and V(D)J recombination of the kappa immunoglobulin light-chain locus: NF-kappaB-dependent and -independent pathways of activation. Mol Cell Biol 1997, 17:3477-3487.
18. Lehr H.A., Mankoff D.A., Corwin D., Santeusanio G., Gown A.M. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997, 45:1559-1565.
19. Levin S.D., Anderson S.J., Forbush K.A., Perlmutter R.M. A dominant-negative transgene defines a role for p56lck in thymopoiesis. Embo J 1993, 12:1671-1680.
20. Linden M., Kirchhof N., Kvitrud M., Van Ness B. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice. Leuk Res 2005, 29:435-444.
21. Langdon W.Y., Harris A.W., Cory S. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl. Oncogene Res 1989, 4:253-258.
22. Alexander W.S., Bernard O., Cory S., Adams J.M. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations. Oncogene 1989, 4:575-581.
23. Biology of Multiple Myeloma (Contemporary Cancer Research) 2006, Humana Press, New York. L.P. Bergsagel, M.W. Kuehl (Eds.).
24. Bazarov A.V., Adachi S., Li S.F., Mateyak M.K., Wei S., Sedivy J.M. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res 2001, 61:1178-1186.
25. Shammah S., Mantovani T.L., Dalla-Favera R., Casali P. Generation of human monoclonal antibodies by transformation of lymphoblastoid B cells with ras oncogene. J Immunol Methods 1993, 160:19-25.
26. Clynes R., Wax J., Stanton L.W., Smith-Gill S., Potter M., Marcu K.B. Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus. Proc Natl Acad Sci U S A 1988, 85:6067-6071.
27. Adams J.M., Harris A.W., Vaux D.L., et al. The transgenic window onlymphoid malignancy. Princess Takamatsu Symp 1989, 20:297-309.
28. Martin P., Santon A., Garcia-Cosio M., Bellas C. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies. Int J Oncol 2005, 27:1023-1028.
29. Ng M.H., Lau K.M., Wong W.S., et al. Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript. Br J Haematol 2003, 123:637-645.
30. Ortega M.M., Faria R.M., Shitara E.S., et al. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma. Leuk Lymphoma 2006, 47:285-289.
31. Kalakonda N., Rothwell D.G., Scarffe J.H., Norton J.D. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001, 98:1555-1560.
32. Rasmussen T., Kuehl M., Lodahl M., Johnsen H.E., Dahl I.M. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005, 105:317-323.
33. Chng W.J., Glebov O., Bergsagel P.L., Kuehl W.M. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007, 20:571-596.
34. Davies F.E., Dring A.M., Li C., et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003, 102:4504-4511.
35. Chesi M., Robbiani D.F., Sebag M., et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13:167-180.
36. Tran P.T., Fan A.C., Bendapudi P.K., et al. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One 2008, 3:e2125.